Vaxcyte, Inc. (PCVX) income statement
NASDAQ · Healthcare · Biotechnology · 507 employees · CEO Grant E. Pickering
- Price
- $62.03 -0.93%
- Market cap
- $9.76B
- Enterprise value
- $9.7B
- Last report
- Q2 '26 filed 2026-08-05
- Next report
- 2026-11-03 EPS est. -$2.11
Income statement
| Income statement | Trend | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $4.99M | $0 | -$4.99M | $5.85M | $0 | |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$4.99M | $0 | $4.99M | -$5.85M | $0 | |
| Research & development | $97.4M | $104M | $94.6M | $132M | $117M | $134M | $148M | $194M | $210M | $242M | $313M | $268M | |
| General & administrative | $15.6M | $17.5M | $19.9M | $21.5M | $23M | $28.6M | $32.7M | $32M | $32.4M | $32.2M | $33.1M | $34.9M | |
| Other operating expenses | $0 | $75M | $0 | $0 | $0 | $0 | $0 | -$4.99M | $0 | $4.99M | -$5.85M | $0 | |
| Operating expenses | $113M | $197M | $114M | $153M | $140M | $162M | $181M | $221M | $242M | $279M | $340M | $303M | |
| Operating income | -$113M | -$197M | -$114M | -$153M | -$140M | -$162M | -$181M | -$226M | -$242M | -$274M | -$346M | -$303M | |
| Interest income | $18.5M | $17.6M | $21.7M | $23.8M | $28.1M | $36.5M | $32.9M | $31.1M | $29.3M | $26.5M | $26.6M | $25.8M | |
| Other non-operating income (gains on investments, FX ...) | -$1.64M | -$15.9M | -$19.5M | -$24.3M | -$292K | -$105M | -$40.1M | -$59.6M | -$29.6M | -$27.8M | -$25.2M | -$7.28M | |
| Total non-operating income | $20.4M | $15.9M | $19.5M | $24.3M | $36.8M | $25.1M | $40.1M | $59.6M | $29.6M | $27.8M | $25.2M | $18.5M | |
| Income before tax | -$92.7M | -$181M | -$95M | -$129M | -$103M | -$137M | -$141M | -$167M | -$213M | -$247M | -$321M | -$284M | |
| Net income | -$92.7M | -$181M | -$95M | -$129M | -$103M | -$137M | -$141M | -$167M | -$213M | -$247M | -$321M | -$284M | |
| EPS (basic) | -$0.91 | -$1.73 | -$0.85 | -$1.10 | -$0.83 | -$1.12 | -$1.04 | -$1.22 | -$1.56 | -$1.81 | -$2.30 | -$1.97 | |
| EPS (diluted) | -$0.91 | -$1.73 | -$0.85 | -$1.10 | -$0.83 | -$1.12 | -$1.04 | -$1.22 | -$1.56 | -$1.81 | -$2.30 | -$1.97 | |
| Shares (basic, weighted) | 102M | 104M | 112M | 117M | 124M | 123M | 136M | 136M | 136M | 136M | 140M | 144M | |
| Shares (diluted, weighted) | 102M | 104M | 112M | 117M | 124M | 123M | 136M | 136M | 136M | 136M | 140M | 144M | |
| Depreciation & amortization | $2.48M | $2.95M | $3.09M | $3.48M | $4.49M | $4.79M | $4.87M | $4.99M | $5.2M | $9.8M | $5.85M | $5.95M | |
| EBITDA | -$109M | -$178M | -$91.9M | -$125M | -$135M | -$52.6M | -$136M | -$162M | -$208M | -$237M | -$315M | -$290M |
| Income statement | Trend | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cost of revenue | $0 | $1.04M | $1.23M | $1.41M | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | -$1.04M | -$1.23M | -$1.41M | $0 | $0 | $0 | $0 | $0 | |
| Research & development | $12.8M | $30.1M | $45.6M | $73.6M | $78.4M | $169M | $332M | $477M | $794M | |
| General & administrative | $5.05M | $5.39M | $0 | $0 | $25.3M | $39.8M | $60.7M | $92.9M | $129M | |
| Other operating expenses | $0 | $5.18M | $0 | $0 | $0 | $23M | $75M | $0 | $0 | |
| Operating expenses | $17.4M | $35.5M | $52.9M | $88.2M | $104M | $232M | $468M | $570M | $924M | |
| Operating income | -$17.8M | -$35.5M | -$54.2M | -$89.6M | -$104M | -$232M | -$468M | -$570M | -$924M | |
| Interest income | $164K | $903K | $632K | $244K | $344K | $8.36M | $62.9M | $110M | $120M | |
| Interest expense | $0 | $75K | $40K | $7K | $7K | $2K | $0 | $0 | $0 | |
| Other non-operating income (gains on investments, FX ...) | $0 | -$6.12M | -$3.92M | -$371K | -$3.6M | -$8.77M | -$65.8M | -$106M | -$157M | |
| Total non-operating income | $595K | $6.05M | $3.88M | $364K | $3.59M | $8.77M | $65.8M | $106M | $157M | |
| Income before tax | -$17.2M | -$29.5M | -$50.3M | -$89.2M | -$100M | -$223M | -$402M | -$464M | -$767M | |
| Net income | -$17.2M | -$29.5M | -$50.3M | -$89.2M | -$100M | -$223M | -$402M | -$464M | -$767M | |
| EPS (basic) | -$4.84 | -$8.12 | -$14.10 | -$2.97 | -$1.93 | -$3.44 | -$4.14 | -$3.80 | -$5.63 | |
| EPS (diluted) | -$4.83 | -$8.12 | -$14.10 | -$2.97 | -$1.93 | -$3.44 | -$4.14 | -$3.80 | -$5.63 | |
| Shares (basic, weighted) | 3.57M | 3.63M | 3.8M | 29.5M | 51.9M | 64.9M | 97.2M | 122M | 136M | |
| Shares (diluted, weighted) | 3.57M | 3.63M | 3.8M | 29.5M | 51.9M | 64.9M | 97.2M | 122M | 136M | |
| Depreciation & amortization | $625K | $1.04M | $1.23M | $1.41M | $3.46M | $9.45M | $10.2M | $15.8M | $24.9M | |
| EBITDA | -$17.2M | -$28.4M | -$49M | -$87.8M | -$96.6M | -$214M | -$392M | -$448M | -$742M |
Standardised from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in USD.
Revenue, operating income and growth
quarterlyMargins
quarterlyCosts as % of revenue
quarterlyThe other statements
Sources
Statements, segment revenue, metrics and estimates are standardised from the company's filings. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30, 10-Q 2024-06-30
Data as of 2026-11-02